Nordic Nanovector ASA (0R6Y)

11.67
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    11.67 - 11.67

0R6Y Overview

Prev. Close
11.89
Day's Range
11.67-11.67
Revenue
-
Open
11.81
52 wk Range
10.72-31.82
EPS
-
Volume
0
Market Cap
1.35B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
10,314
P/E Ratio
-
Beta
-
1-Year Change
-58.68%
Shares Outstanding
116,035,298
Next Earnings Date
19 Jul 2022
What is your sentiment on Nordic Nanovector ASA?
or
Vote to see community's results!

Nordic Nanovector ASA News

Nordic Nanovector ASA Company Profile

Nordic Nanovector ASA Company Profile

Employees
40
Market
Norway

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company’s lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell